Patents Assigned to Institute National de la Sante et de la Recherche Medicale-Inserm
-
Patent number: 11573241Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.Type: GrantFiled: March 8, 2017Date of Patent: February 7, 2023Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de ParisInventors: Maryam Mehrpour, Raphael Rodriguez, Ahmed Hamai, Trang Mai
-
Patent number: 11510896Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.Type: GrantFiled: October 20, 2017Date of Patent: November 29, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Manuel Rosa-Calatrava, Olivier Terrier, Anaïs Proust, Vincent Moules
-
Patent number: 9683986Abstract: A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.Type: GrantFiled: December 17, 2012Date of Patent: June 20, 2017Assignees: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, HOSPICES CIVILS DE LYON, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Alain Kfoury, Isabelle Coste-Invernizzi, Serge Lebecque, Toufic Renno
-
Patent number: 9389233Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.Type: GrantFiled: June 12, 2009Date of Patent: July 12, 2016Assignees: Institute National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Assistance Publique-Hopitaux de Paris, Centre Henri Becquerel, Universite Paris Descartes, Universite Pierre et Marie Curie (PARIS 6), Universite Paris-SudInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Patent number: 9259597Abstract: A phacoemulsificator for the removal of lens tissue, wherein the phacoemulsificator contains: a power source configured to provide pulsed electrical power, and a pump configured to provide vacuum, characterized in that the phacoemulsificator contains at least one eye ring connectable to the pump wherein the proximal end of said eye ring is suitable to be applied onto an ocular globe and means to generate ultrasound beam connectable to the power source wherein said means are fixed on the distal end of the eye ring.Type: GrantFiled: August 26, 2009Date of Patent: February 16, 2016Assignees: EYE TECH CARE, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Fabrizio Romano, Philippe Chapuis, Laurent Farcy, Thomas Charrel
-
Patent number: 9121858Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.Type: GrantFiled: October 12, 2012Date of Patent: September 1, 2015Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris DescartesInventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
-
Patent number: 8933050Abstract: The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver cancer such as hepatocellular carcinoma (HCC).Type: GrantFiled: September 2, 2010Date of Patent: January 13, 2015Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Assistance Publique—Hopitaux de ParisInventors: Gérard Friedlander, Laurent Beck, Christine Salaün, Christine Leroy
-
Patent number: 8709383Abstract: The invention relates to using persistent luminescence nanoparticles, functionalised if necessary, in the form of an diagnosis agent for an in vivo optical imaging. Said nanoparticles are preferably consist of a compound selected from a group comprising (1) silicates, aluminates, aluminosilicates, germanates, titanates, oxysulphides, phosphates and vanadates, wherein said compounds contain at least one type of metal oxide, (2) the sulphides comprise at least one metal ion selected from zinc, strontium and calcium, and (3) metal oxides, wherein said compounds is doped with at least one rare earth ion, and possibly with at least one transition metal ion. In a preferred embodiment, the diagnosis agent is used for an organism vascularization imaging. A method and kit for detecting or quantifying in vitro a substance of biological or chemical interest in a sample by using said pre-functionalised nanoparticles are also disclosed.Type: GrantFiled: October 30, 2006Date of Patent: April 29, 2014Assignees: Centre National de la Recherche Scientifique (CNRS), Institute National de la Sante et de la Recherche Medicale (INSERM)Inventors: Daniel Scherman, Michel Bessodes, Corinne Chaneac, Didier Louis Gourier, Jean-Pierre Jolivet, Quentin Le Masne De Chermont, Serge Maitrejean, Fabienne Sylvie Pelle
-
Patent number: 8679500Abstract: The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.Type: GrantFiled: May 14, 2010Date of Patent: March 25, 2014Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Bretagne Occidentale, Centre National de la Recherche Scientifique (CNRS)Inventors: Laurence Boumsell, Christian Berthou, Karine Lester, Severine Loisel, Martine Cerruti
-
Patent number: 8324152Abstract: The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.Type: GrantFiled: January 4, 2006Date of Patent: December 4, 2012Assignee: Institute National de la Sante et de la Recherche Medicale (INSERM)Inventors: Alain Tedgui, Ziad Mallat
-
Publication number: 20110009779Abstract: The present invention relates to a method of treating an ocular pathology by generating high intensity focused ultrasound onto at least one eye's area, said method comprises at least the following steps of: —positioning onto the eye a device capable of directing high intensity focused ultrasound onto at least one annular segment, —and generating high intensity focused ultrasound energy onto said segment to treat at least one annular segment in the eye. Another embodiment of the invention concerns a device for treatment of an ocular pathology comprising at least one eye ring (1) wherein the proximal end of said eye ring (1) is suitable to be applied onto the globe and circular means (2,17) to generate ultrasound beam fixed on the distal end of the eye ring (1) capable of treating the whole circumference of the eye in one step.Type: ApplicationFiled: February 18, 2009Publication date: January 13, 2011Applicants: Eye Tech Care, Institute National De La Sante Et De La Recherche Medicale (INSERM)Inventors: Fabrizio Romano, Cyril Lafon, Jean-Yves Chapelon, Francoise Chavrier, Alain Birer
-
Publication number: 20100129371Abstract: The invention concerns a method for obtaining an antiserum directed against a proteinic toxin by administering to an animal a solution comprising a genetic construct encoding a toxin immunogenic fragment, then applying an electric field in the administering zone, and isolating the serum. The invention also concerns the antiserum obtainable by the method as well as the use of the solution for making a medicine for preventing or treating a toxic effect related to absorption by a mammal of a toxin. The invention is characterized in that said medicine is formulated to be administered by electrotransfer.Type: ApplicationFiled: July 28, 2006Publication date: May 27, 2010Applicants: Centre National de la Recherche Scientifique (CNRS), Institute Pasteur, Institute National de la Sante et de la Recherche Medicale (INSERM), Universite Rene DescartesInventors: Daniel Scherman, Pascal Bigey, Capucine Trollet, Michel R. Popoff, Yannick Pereira
-
Patent number: 7582797Abstract: The invention relates to derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.Type: GrantFiled: August 6, 2004Date of Patent: September 1, 2009Assignee: Institute National de la Sante et de la Recherche Medicale (Inserm)Inventors: Bernard Pierre Roques, Nicolas Inguimbert, Marie-Claude Fournie-Zaluski, Pierre Corvol, Catherine Llorens-Cortes
-
Patent number: 7534877Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBE30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: September 15, 2005Date of Patent: May 19, 2009Assignees: Institute National de la Sante et de la Recherche Medicale-Inserm, Assitance Publique-Hopitaux de Paris, Institut PasteurInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 7030234Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: November 22, 2002Date of Patent: April 18, 2006Assignees: Institute National de la Sante et de la Recherche Medicale-Inserm, Assistance Publique-Hopitaux de Paris, Institute PasteurInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Patent number: 6649615Abstract: The present invention relates to a method for inhibiting hepatic fibrogenesis, especially liver fibrogenesis, which method comprises administering an effective amount of an alpha-adrenergic receptor antagonist to a patient in need of such treatment.Type: GrantFiled: April 23, 2002Date of Patent: November 18, 2003Assignee: Institute National de la Sante et de la Recherche Medicale (INSERM)Inventors: Liliane Dubuisson, Alexis Desmouliere, Jean Rosenbaum
-
Patent number: 6635431Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.Type: GrantFiled: May 28, 1999Date of Patent: October 21, 2003Assignees: Genset, S.A., Institute National de la Sante et de la Recherche Medicale (INSERM)Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
-
Publication number: 20030157660Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.Type: ApplicationFiled: November 22, 2002Publication date: August 21, 2003Applicant: Institute National de la Sante et de La Recherche Medicale-InsermInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi
-
Publication number: 20030068632Abstract: Methods are described for assessing an individual's risk for developing early-onset glaucoma, for developing glaucoma with a high intraocular pressure at onset of disease, or for developing glaucoma with a high visual field score and/or a high cup/disk ratio, by assessing the ApoE alleles and/or the ApoE gene promoter alleles of the individual. In individuals carrying mutations in the TIGR gene, the presence of an ApoE4 allele is indicative of an increased risk of developing early-onset glaucoma. In individuals carrying mutations in the TIGR gene promoter, the presence of an ApoE4 allele is indicative of a decreased risk of developing glaucoma with a high intraocular pressure at onset of disease. The combination of an ApoE4 allele and a “T” allele of a ApoE gene promoter (at −491) in an individual carrying a mutation in the TIGR gene is also indicative of an increased risk of developing early-onset glaucoma.Type: ApplicationFiled: May 16, 2002Publication date: April 10, 2003Applicant: Institute National de la Sante et de la Recherche Medicale (INSERM)Inventor: Henri-Jean Garchon
-
Patent number: 6509018Abstract: The invention provides peptides which are expressed by the env gene of a non-M, non-O HIV-1 virus, in particular a strain designated YBF30. The invention also provides fragments of the peptides that including the V3 loop region and their corresponding nucleotide sequences. The invention further provides kits including diagnostic reagents containing these molecules or immunogenic compositions containing these peptides, as well as methods for screening and typing non-M, non-O HIV-1 viruses and HIV-1 viruses expressing these peptide and/or nucleotide sequences.Type: GrantFiled: August 27, 1999Date of Patent: January 21, 2003Assignee: Institute National de la Sante et de la Recherche Medicale-InsermInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi